AWM Investment Company Inc. Invests $1.94 Million in Palvella Therapeutics, Inc. $PVLA

Key Points

• AWM Investment Company Inc. acquired a new position in Palvella Therapeutics, purchasing 69,416 shares valued at approximately $1.94 million, now owning about 0.63% of the company.
• Analysts are optimistic about Palvella Therapeutics, with several brokerages assigning a “buy” rating and setting price targets ranging from $54.00 to $90.00, contributing to a consensus target of $58.50.
• Palvella Therapeutics' stock has seen a decrease of 2.7% recently, with current stock prices around $52.71, despite having a 52-week high of $57.19.

AWM Investment Company Inc. bought a new position in Palvella Therapeutics, Inc. (NASDAQ:PVLA - Free Report) during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 69,416 shares of the company's stock, valued at approximately $1,943,000. AWM Investment Company Inc. owned about 0.63% of Palvella Therapeutics as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in PVLA. Spire Wealth Management bought a new position in Palvella Therapeutics in the 1st quarter worth about $70,000. Citadel Advisors LLC purchased a new position in shares of Palvella Therapeutics in the 4th quarter worth about $125,000. Toronto Dominion Bank purchased a new position in shares of Palvella Therapeutics in the 4th quarter worth about $159,000. Cresset Asset Management LLC purchased a new position in shares of Palvella Therapeutics in the 4th quarter worth about $251,000. Finally, Renaissance Technologies LLC purchased a new position in shares of Palvella Therapeutics in the 4th quarter worth about $256,000. 40.11% of the stock is currently owned by institutional investors.

Palvella Therapeutics Trading Down 0.7%

NASDAQ PVLA traded down $0.40 on Monday, hitting $55.28. The company's stock had a trading volume of 33,398 shares, compared to its average volume of 97,918. Palvella Therapeutics, Inc. has a 52-week low of $11.17 and a 52-week high of $58.22. The company's 50-day simple moving average is $39.37 and its 200 day simple moving average is $29.24. The firm has a market cap of $611.40 million, a P/E ratio of -4.57 and a beta of -0.04.

Palvella Therapeutics (NASDAQ:PVLA - Get Free Report) last released its quarterly earnings data on Thursday, August 14th. The company reported ($0.86) earnings per share for the quarter, missing the consensus estimate of ($0.78) by ($0.08). On average, research analysts forecast that Palvella Therapeutics, Inc. will post -3.69 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on PVLA. HC Wainwright upped their price objective on Palvella Therapeutics from $38.00 to $75.00 and gave the stock a "buy" rating in a report on Friday, August 15th. Canaccord Genuity Group increased their target price on Palvella Therapeutics from $52.00 to $66.00 and gave the company a "buy" rating in a report on Tuesday, August 19th. Truist Financial began coverage on Palvella Therapeutics in a report on Monday, July 21st. They set a "buy" rating and a $56.00 target price for the company. Lifesci Capital began coverage on Palvella Therapeutics in a report on Monday, August 4th. They set an "outperform" rating and a $90.00 target price for the company. Finally, Raymond James Financial set a $54.00 target price on Palvella Therapeutics and gave the company an "outperform" rating in a report on Tuesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating and ten have issued a Buy rating to the company. According to MarketBeat.com, Palvella Therapeutics has a consensus rating of "Buy" and an average target price of $58.50.

Palvella Therapeutics Company Profile

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.